Perros Frédéric, de Man Frances S, Bogaard Harm J, Antigny Fabrice, Simonneau Gérald, Bonnet Sébastien, Provencher Steeve, Galiè Nazzareno, Humbert Marc
From the University Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre, France (F.P., F.A., G.S., M.H.); AP-HP, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin Bicêtre, France (F.P., F.A., G.S., M.H.); Inserm UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France (F.P., F.A., G.S., M.H.); Department of Pulmonology, VU University Medical Centre, Amsterdam, The Netherlands (F.S.d.M., H.J.B.); Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Ville de Québec, Canada (S.B., S.P.); Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Italy (N.G.).
Circ Heart Fail. 2017 Apr;10(4). doi: 10.1161/CIRCHEARTFAILURE.116.003703.
Contrasting with the major attention that left heart failure has received, right heart failure remains understudied both at the preclinical and clinical levels. However, right ventricle failure is a major predictor of outcomes in patients with precapillary pulmonary hypertension because of pulmonary arterial hypertension, and in patients with postcapillary pulmonary hypertension because of left heart disease. In pulmonary hypertension, the status of the right ventricle is one of the most important predictors of both morbidity and mortality. Paradoxically, there are currently no approved therapies targeting the right ventricle in pulmonary hypertension. By analogy with the key role of β-blockers in the management of left heart failure, some authors have proposed to use these agents to support the right ventricle function in pulmonary hypertension. In this review, we summarize the current knowledge on the use of β-blockers in pulmonary hypertension.
与左心衰竭受到的主要关注形成对比的是，右心衰竭在临床前和临床层面都仍未得到充分研究。然而，右心室衰竭是毛细血管前性肺动脉高压（由肺动脉高压引起）患者以及毛细血管后性肺动脉高压（由左心疾病引起）患者预后的主要预测指标。在肺动脉高压中，右心室状态是发病率和死亡率的最重要预测指标之一。矛盾的是，目前在肺动脉高压中尚无获批的针对右心室的疗法。类比β受体阻滞剂在左心衰竭管理中的关键作用，一些作者提议使用这些药物来支持肺动脉高压患者的右心室功能。在本综述中，我们总结了目前关于β受体阻滞剂在肺动脉高压中应用的知识。
